

Biagio De Angelis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6194506/publications.pdf>

Version: 2024-02-01

65
papers

2,049
citations

331670

21
h-index

254184

43
g-index

66
all docs

66
docs citations

66
times ranked

2804
citing authors

#	ARTICLE	IF	CITATIONS
1	T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. <i>Blood</i> , 2009, 113, 6392-6402.	1.4	458
2	Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. <i>OncolImmunology</i> , 2018, 7, e1433518.	4.6	120
3	Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 1876-1885.	1.4	106
4	High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. <i>Blood</i> , 2011, 117, 3353-3362.	1.4	100
5	Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. <i>OncolImmunology</i> , 2018, 7, e1378843.	4.6	88
6	Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. <i>Frontiers in Immunology</i> , 2019, 10, 957.	4.8	88
7	Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). <i>Blood</i> , 2009, 114, 4784-4791.	1.4	86
8	Zoledronic acid boosts γ T-cell activity in children receiving β 2-microglobulin-depleted grafts from an HLA-haplo-identical donor. <i>OncolImmunology</i> , 2017, 6, e1216291.	4.6	76
9	ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. <i>Genome Biology</i> , 2021, 22, 51.	8.8	71
10	Interleukin 15 Provides Relief to CTLs from Regulatory T Cell-Mediated Inhibition: Implications for Adoptive T Cell-Based Therapies for Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 106-117.	7.0	68
11	Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma. <i>Cancer Research</i> , 2018, 78, 3337-3349.	0.9	64
12	Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 1102-1115.	7.2	63
13	CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells. <i>Haematologica</i> , 2021, 106, 987-999.	3.5	42
14	Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 191.	17.0	39
15	Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. <i>Frontiers in Oncology</i> , 2020, 10, 489.	2.8	38
16	Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy. <i>Cells</i> , 2021, 10, 14.	4.1	34
17	Stimuli-responsive nanoparticle-assisted immunotherapy: a new weapon against solid tumours. <i>Journal of Materials Chemistry B</i> , 2020, 8, 1823-1840.	5.8	32
18	Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γ Memory T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2717.	4.8	31

#	ARTICLE	IF	CITATIONS
19	Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. <i>Neuro-Oncology</i> , 2022, 24, 1150-1163.	1.2	31
20	Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 382-393.	0.9	30
21	Overcoming Challenges in CAR T-cell Product CGMP Release. <i>Molecular Therapy</i> , 2016, 24, 845-846.	8.2	25
22	Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. <i>Leukemia Research</i> , 2014, 38, 236-242.	0.8	24
23	DNA Methylation Profiling for Diagnosing Undifferentiated Sarcoma with Capicua Transcriptional Receptor (CIC) Alterations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1818.	4.1	24
24	Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2021, 12, 755639.	4.8	23
25	Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. , 2021, 9, e001930.		21
26	Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. <i>Acta Neuropathologica</i> , 2021, 142, 537-564.	7.7	21
27	PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches. <i>Cancers</i> , 2021, 13, 4040.	3.7	21
28	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
29	CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. <i>Frontiers in Pharmacology</i> , 2020, 11, 1230.	3.5	20
30	WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene. <i>Oncotarget</i> , 2015, 6, 28223-28237.	1.8	17
31	Expression profiles of exosomal miRNAs isolated from plasma of patients with desmoplastic small round cell tumor. <i>Epigenomics</i> , 2019, 11, 489-500.	2.1	16
32	Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers. <i>Diagnostics</i> , 2022, 12, 173.	2.6	16
33	GD2 redirected CAR T and activated NK-cell-mediated secretion of IFN γ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. , 2021, 9, e001502.		15
34	PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism. <i>Molecular Oncology</i> , 2022, 16, 188-205.	4.6	15
35	Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. <i>Leukemia Research</i> , 2008, 32, 255-261.	0.8	13
36	Time 2EVOLVE: predicting efficacy of engineered T-cells “ how far is the bench from the bedside? . , 2022, 10, e003487.		13

#	ARTICLE	IF	CITATIONS
37	NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles. <i>Seminars in Hematology</i> , 2020, 57, 175-184.	3.4	10
38	Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. , 2021, 9, e001514.		10
39	Preferentially Expressed Antigen of Melanoma (PRAME)-Specific Cytotoxic T-Lymphocytes (CTLs) and Transgenic T Cells To Target Chronic Myelogenous Leukemia (CML).. <i>Blood</i> , 2007, 110, 2761-2761.	1.4	10
40	Gene Therapy to Improve Migration of T Cells to the Tumor Site. <i>Methods in Molecular Biology</i> , 2010, 651, 103-118.	0.9	9
41	CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells. <i>Blood</i> , 2018, 132, 3491-3491.	1.4	8
42	Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells. <i>Cancers</i> , 2021, 13, 3298.	3.7	5
43	FGFR1 is a potential therapeutic target in neuroblastoma. <i>Cancer Cell International</i> , 2022, 22, 174.	4.1	5
44	Establishment and Characterization of a Cell Line (S-RMS1) Derived from an Infantile Spindle Cell Rhabdomyosarcoma with SRF-NCOA2 Fusion Transcript. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5484.	4.1	4
45	Identification of New Soluble Factors Correlated With the Development of Graft Failure After Haploidentical Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 613644.	4.8	3
46	Generation Of Virus-Specific Cytotoxic T Lymphocytes (CTLs) Resistant to the Immunosuppressive Drug Tacrolimus (FK506). <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 135.	2.0	2
47	Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?. <i>Frontiers in Immunology</i> , 2021, 12, 634031.	4.8	2
48	Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children. <i>Blood</i> , 2019, 134, 1341-1341.	1.4	2
49	Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients. <i>Blood</i> , 2014, 124, 1809-1809.	1.4	2
50	IL15 Enhances Proliferation and Effector Function of Antigen-Specific Cytotoxic T Lymphocytes (CTLs) and Mitigates the Suppressive Action of Regulatory T Cells (Tregs).. <i>Blood</i> , 2009, 114, 4088-4088.	1.4	1
51	Analysis of Bone Marrow Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib.. <i>Blood</i> , 2012, 120, 2795-2795.	1.4	1
52	S1635 ACADEMIC, PHASE1 TRIAL ON T CELLS EXPRESSING BOTH CD19 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA. <i>HemaSphere</i> , 2019, 3, 755.	2.7	1
53	A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma. <i>Blood</i> , 2019, 134, 2069-2069.	1.4	1
54	MB-64ADOPTIVE CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA BASED ON T CELLS REDIRECTED TOWARD TUMOR CELLS BY PRAME SPECIFIC β 2TCR GENE MODIFICATION. <i>Neuro-Oncology</i> , 2016, 18, iii111.3-iii111.	1.2	0

#	ARTICLE	IF	CITATIONS
55	TMOD-14. INNOVATIVE 3D MODEL FOR THE ESTABLISHMENT OF PRIMARY PAEDIATRIC LOW-GRADE GLIOMA (LGG) CULTURES: NEW PLATFORM FOR ADVANCED PRECLINICAL STUDIES OF INNOVATIVE AND IMMUNOTHERAPEUTIC APPROACHES. <i>Neuro-Oncology</i> , 2019, 21, ii123-ii124.	1.2	0
56	IMMU-12. NOVEL APPROACH FOR THE TREATMENT OF PEDIATRIC HIGH-GRADE GLIOMAS WITH THE COMBINATION OF ONCOLYTIC ADENOVIRUSES AND GENE THERAPY ENCODING A BiTE DIRECTED TO THE EphA2 TUMOR ANTIGEN.. <i>Neuro-Oncology</i> , 2019, 21, ii95-ii95.	1.2	0
57	Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. <i>Blood</i> , 2006, 108, 2158-2158.	1.4	0
58	Polyclonal PRAME-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3899-3899.	1.4	0
59	The Interferon Score Towards Interferon Alpha Tailored Therapy In Essential Thrombocythemia. <i>Blood</i> , 2013, 122, 4073-4073.	1.4	0
60	A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia. <i>Blood</i> , 2014, 124, 1850-1850.	1.4	0
61	Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. <i>Blood</i> , 2015, 126, 1570-1570.	1.4	0
62	Clinical Outcome and Immune Recovery after Adoptive Infusion of BPX-501 Cells (donor T cells) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 47 Given $\hat{\pm}/\hat{\pm}^2$ T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (HSCT). <i>Blood</i> , 2016, 128, 2286-2286.	1.4	0
63	Zoledronic Acid Boosts $\hat{\pm}/\hat{\pm}^2$ T-Cell Activity in Children Receiving $\hat{\pm}/\hat{\pm}^2$ T and CD19+ CELL-Depleted Grafts from a Haplo-Identical DONOR. <i>Blood</i> , 2016, 128, 5771-5771.	1.4	0
64	Patient-Derived Chimeric Antigen Receptor T-Cell Production Based on a Gammaretroviral Vector Platform Is Not Associated with Generation of CAR+ Leukemia Blasts. <i>Blood</i> , 2018, 132, 2204-2204.	1.4	0
65	IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii362-iii362.	1.2	0